Based on promising findings from ongoing clinical and non-clinical
studies, UCB awarded NPT a major program milestone of $5 million.
SAN DIEGO–(BUSINESS WIRE)–Neuropore Therapies, Inc. announced today that they have successfully
achieved a key program milestone in their collaboration with UCB. After
successful completion of a randomized, double-blind, placebo controlled
single ascending dose clinical study and additional non-clinical
studies, UCB has awarded NPTTM a progression milestone of $5
“We are very pleased with UCB’s decision to proceed with the development
of this novel therapeutic candidate that initially arose from
Neuropore’s drug-discovery platform. This is an important milestone for
Neuropore and reflects UCB’s continued commitment to a promising
therapeutic opportunity for the treatment of Parkinson’s disease,”
commented Doug Bonhaus, Ph.D., Neuropore’s COO.
About Parkinson’s disease
Parkinson’s disease (PD) is the second most common neurodegenerative
disorder after Alzheimer’s disease. There are an estimated seven to ten
million patients with PD worldwide. Current treatments for PD are
effective at managing the early motor symptoms of the disease, mainly
through the use of levodopa and dopamine agonists. As the disease
progresses and dopaminergic neurons continue to be lost, these drugs
eventually become less effective at treating the symptoms. Currently
there are no approved disease modifying treatments for PD.
About Neuropore Therapies, Inc. (NPTTM)
Neuropore Therapies is a pharmaceutical company committed to the
discovery and development of disease-modifying treatments for
neurodegenerative disorders, including Parkinson’s disease and
Our approach is based on the fundamental concept that the pathological
accumulation of misfolded and aggregated neurotoxic proteins is the
underlying basis of these disorders. Our therapeutic candidates directly
target these proteins and restore cellular autophagy mechanisms to
degrade and dispose of these neurotoxic proteins.
The NPTTM Discovery and Development Platform utilizes
structure-based drug design, dynamic molecular modeling, and proprietary
in vitro and in vivo models to discover and develop novel small molecule
drug candidates that facilitate the cellular clearance of toxic
misfolded proteins and provide therapeutic benefit to patients with
neurodegenerative disorders. NPTTM200-11 is the most advanced
product arising from this platform.
In 2014 Neuropore Therapies entered into a collaboration and world-wide
exclusive license agreement with UCB.
For more information visit www.neuropore.com.
UCB, Brussels, Belgium (www.ucb.com)
is a global biopharmaceutical company focused on the discovery and
development of innovative medicines and solutions to transform the lives
of people living with severe diseases of the immune system or of the
central nervous system. With more than 7700 people in approximately 40
countries, the company generated revenue of € 3.9 billion in 2015. UCB
is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter:
Forward looking statements
This press release contains forward-looking statements based on current
information, projections and assumptions of management. Statements in
this press release that are not strictly historical in nature are
forward-looking statements. By their nature forward-looking statements
are not guarantees of future performance and are subject to risks and
uncertainties which may cause actual results to differ materially from
the forward-looking statements contained in this press release.
Important factors that could result in such differences include the
risks and uncertainties inherent in drug discovery, development,
approval and commercialization, collaborations with others, and the fact
that past results of clinical trials and regulatory decisions may not be
indicative of future trial results or regulatory decisions.
Neuropore Therapies, Inc.
Doug Bonhaus, Ph.D.